Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1932 1
1939 1
1941 1
1947 2
1952 1
1955 1
1956 1
1957 1
1958 1
1961 1
1964 1
1965 1
1967 2
1968 5
1969 6
1970 2
1971 7
1972 4
1973 4
1974 2
1975 4
1976 2
1977 1
1978 4
1979 1
1980 1
1981 6
1982 3
1983 2
1984 3
1985 3
1986 4
1987 5
1988 9
1989 6
1990 11
1991 9
1992 16
1993 14
1994 13
1995 23
1996 21
1997 21
1998 14
1999 14
2000 10
2001 15
2002 9
2003 11
2004 9
2005 7
2006 18
2007 31
2008 19
2009 28
2010 31
2011 28
2012 41
2013 29
2014 34
2015 32
2016 56
2017 43
2018 60
2019 86
2020 84
2021 82
2022 77
2023 64
2024 60
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,109 results

Results by year

Filters applied: . Clear all
Page 1
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Castro M, et al. Among authors: graham nmh. N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21. N Engl J Med. 2018. PMID: 29782217 Free article. Clinical Trial.
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, Paggiaro P, Cho SH, Fokkens WJ, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD, Mannent LP. Bachert C, et al. Among authors: graham nmh. Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19. Lancet. 2019. PMID: 31543428 Clinical Trial.
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, Suprun M, Estrada Y, Xu H, Peng X, Silverberg JI, Menter A, Krueger JG, Zhang R, Chaudhry U, Swanson B, Graham NMH, Pirozzi G, Yancopoulos GD, D Hamilton JD. Guttman-Yassky E, et al. Among authors: graham nmh. J Allergy Clin Immunol. 2019 Jan;143(1):155-172. doi: 10.1016/j.jaci.2018.08.022. Epub 2018 Sep 5. J Allergy Clin Immunol. 2019. PMID: 30194992 Free article. Clinical Trial.
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, Hultsch T, Chen Z, Pirozzi G, Graham NMH, Shumel B. de Bruin-Weller M, et al. Among authors: graham nmh. Br J Dermatol. 2018 May;178(5):1083-1101. doi: 10.1111/bjd.16156. Epub 2018 Mar 25. Br J Dermatol. 2018. PMID: 29193016 Free article. Clinical Trial.
Dementia after traumatic brain injury.
Graham NS, Sharp DJ. Graham NS, et al. BMJ. 2023 Oct 19;383:2065. doi: 10.1136/bmj.p2065. BMJ. 2023. PMID: 37857435 No abstract available.
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic A, Ming JE, Radin AR, Krueger JG, Graham N, Yancopoulos GD, Pirozzi G, Guttman-Yassky E. Hamilton JD, et al. Among authors: graham n. J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300. doi: 10.1016/j.jaci.2014.10.013. J Allergy Clin Immunol. 2014. PMID: 25482871 Free article. Clinical Trial.
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M. Deleuran M, et al. Among authors: graham nmh. J Am Acad Dermatol. 2020 Feb;82(2):377-388. doi: 10.1016/j.jaad.2019.07.074. Epub 2019 Jul 30. J Am Acad Dermatol. 2020. PMID: 31374300 Free article. Clinical Trial.
Alzheimer's Disease International.
Graham N, Brodaty H. Graham N, et al. Int J Geriatr Psychiatry. 1997 Jul;12(7):691-2. Int J Geriatr Psychiatry. 1997. PMID: 9251927 No abstract available.
Alzheimer's Disease International.
Graham N. Graham N. Int Psychogeriatr. 1997 Mar;9(1):5-6. doi: 10.1017/s1041610297004146. Int Psychogeriatr. 1997. PMID: 9195273 No abstract available.
1,109 results